Efficacy of Infigratinib

Infigratinib/Infigratinib (Infigratinib) is primarily used to treat a rare type of cancer called cholangiocarcinoma (Cholangiocarcinoma), especially those with specific genetic mutations. This drug works in the following areas:

1.Inhibit cancer cell growth:Infitinib/Infigratinib’s mechanism of action involves inhibiting a protein called fibroblast growth factor receptor (FGFR). In some patients with cholangiocarcinoma, FGFR activity is abnormally high. By inhibiting FGFR, infigratinib can slow or stop the growth and spread of cancer cells, thereby controlling the progression of cancer.

2.Improve survival rate: Clinical trial data show that Infitinib/Infigratinib can significantly improve survival rate in patients with specific genetic variant cholangiocarcinoma. For those patients with activating FGFR2 gene fusions or rearrangements, infigratinib may provide an effective treatment option to extend relapse-free survival (Relapse-Free Survival, RFS).

3.Reducing symptoms: Patients with cholangiocarcinoma usually experience a series of symptoms, including jaundice, abdominal pain, weight loss, etc. By controlling the growth of cancer, Infigratinib can reduce these symptoms and improve patients' quality of life.

4.Sustained remission: For some patients, Infitinib/The therapeutic effects of Infigratinib can last for a long time, even years, which helps keep the cancer in remission and prolong patient survival.

However, it should be emphasized that the efficacy of infigratinib/infigratinib varies depending on the individual patient's circumstances. The specific effectiveness of treatment depends on the patient's genotype, the severity of the cancer and other factors. During treatment, patients need to work closely with their doctors and receive regular medical monitoring to evaluate the effectiveness of the treatment and make adjustments as needed. Infigratinib/Infigratinib represents an important advance in the treatment of cholangiocarcinoma, providing new hope for patients with specific genetic alterations.

Infigratinib/Infigratinib It is not currently available in the country, and it is unlikely to be included in medical insurance. Patients cannot purchase it domestically and can only purchase it through overseas channels. Foreign Infigratinib/Infigratinib only has original drugs, only American original drugs, and the price is as high as about 200,000.